Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...
Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...
Windows’ built-in Deployment Image Servicing and Management (DISM) command, a.k.a. dism.exe, is something of a Swiss Army knife when it comes to working on Windows OS images. Among its many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback